NASDAQ:PLRZ Polyrizon (PLRZ) Stock Price, News & Analysis $9.78 -0.23 (-2.25%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Polyrizon Stock (NASDAQ:PLRZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Polyrizon alerts:Sign Up Key Stats Today's Range$9.49▼$10.3750-Day Range$8.87▼$14.5152-Week Range$2.88▼$18.20Volume18,068 shsAverage Volume61,622 shsMarket Capitalization$23.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Polyrizon Ltd. is a biotechnology company developing nasal and respiratory-care products based on proprietary hydrogel technology. Its platform is designed to create a physical barrier on mucosal surfaces, potentially helping limit exposure to allergens, pollutants, and other airborne particles. The company’s product candidates are focused primarily on intranasal applications, including solutions intended for allergic rhinitis and other upper-respiratory conditions. Polyrizon has described its technology as mucoadhesive, meaning that the hydrogels are designed to remain on nasal surfaces for an extended period while supporting localized protection. Polyrizon is headquartered in Israel and is advancing its platform through product development and clinical or regulatory activities. The company’s programs and commercialization plans remain subject to development, testing, and applicable regulatory approvals.AI Generated. May Contain Errors. Read More Polyrizon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScorePLRZ MarketRank™: 0.80341767121 of 5 starsPolyrizon scored higher than 16% of companies evaluated by MarketBeat, and ranked 832nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPolyrizon has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePolyrizon has only been the subject of 1 research reports in the past 90 days.Read more about Polyrizon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPolyrizon has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.09% of the float of Polyrizon has been sold short.Short Interest Ratio / Days to CoverPolyrizon has a short interest ratio ("days to cover") of 1.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Polyrizon has recently decreased by 8.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolyrizon does not currently pay a dividend.Dividend GrowthPolyrizon does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for PLRZ on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Polyrizon insiders have not sold or bought any company stock.Percentage Held by InstitutionsPolyrizon has minimal institutional ownership at this time.Read more about Polyrizon's insider trading history. Receive PLRZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Polyrizon and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRZ Stock News HeadlinesPolyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery PlatformOctober 5, 2026 | tipranks.comPolyrizon Files New U.S. Patent Application Covering Nasal Drug DeliveryOctober 5, 2026 | rttnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 19 at 1:00 AM | Base Camp Trading (Ad)Polyrizon Files New U.S. Patent Application for Mucoadhesive Nasal Drug Delivery PlatformOctober 5, 2026 | quiverquant.comQPolyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery PlatformOctober 5, 2026 | globenewswire.comPolyrizon Files First-Half 2026 Results Showing Higher Assets and Wider LossSeptember 28, 2026 | tipranks.comPolyrizon Reports Enrollment Of First Patient In Trial For Allergy Nasal Spray NASARIXSeptember 22, 2026 | rttnews.comPolyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy BlockerSeptember 22, 2026 | globenewswire.comSee More Headlines PLRZ Stock Analysis - Frequently Asked Questions How have PLRZ shares performed this year? Polyrizon's stock was trading at $8.49 at the beginning of 2026. Since then, PLRZ shares have increased by 16.1% and is now trading at $9.8590. How were Polyrizon's earnings last quarter? Polyrizon Ltd. (NASDAQ:PLRZ) announced its earnings results on Monday, September, 28th. The company reported ($0.40) EPS for the quarter. When did Polyrizon's stock split? Polyrizon shares reverse split before market open on Friday, November 28th 2025.A 1-6 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Polyrizon IPO? Polyrizon (PLRZ) raised $4 million in an initial public offering on Tuesday, October 29th 2024. The company issued 958,903 shares at a price of $4.38 per share. How do I buy shares of Polyrizon? Shares of PLRZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings9/28/2026Today10/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PLRZ's financial health is in the Green zone, according to TradeSmith. PLRZ has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PLRZ Previous SymbolNASDAQ:PLRZ CIK1893645 Webwww.polyrizon-biotech.com Phone972-55-433-5665FaxN/AEmployees1Year Founded2005Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio36.37 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.05 per share Price / Book0.75Miscellaneous Outstanding Shares2,430,000Free FloatN/AMarket Cap$23.75 million OptionableN/A Beta-1.20 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PLRZ) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
